Core Insights - Transgene is advancing its individualized neoantigen therapeutic vaccine, TG4050, which has shown durable clinical outcomes in head and neck squamous cell carcinoma (HNSCC) and potential to prevent cancer relapse [1][4][6] - The company has sufficient financial resources to support its operations until early 2028, following a successful fundraising of approximately €105 million and the conversion of €39 million debt into shares [21][26] - The randomized Phase 2 part of the clinical trial for TG4050 is nearing completion, with the primary endpoint being two-year disease-free survival [10][11] Clinical Development - TG4050 has demonstrated a 100% disease-free survival rate after more than two years of follow-up in the Phase 1 trial, meeting all trial endpoints [7][8] - A new Phase 1 trial for a second indication in operable solid tumors is planned to start in 2026, reflecting the strategy to expand the clinical evaluation of the myvac® platform [2][12] - Positive results from the Phase 1 trial of BT-001 support further clinical development, showing antitumoral activity in patients with advanced refractory tumors [15][17] Financial Performance - Operating revenue for 2025 was €7.2 million, an increase from €6.4 million in 2024, primarily driven by research tax credits [22][43] - The company reported a net loss of €37.5 million in 2025, compared to a net loss of €34.0 million in 2024, with a net cash burn of €38.2 million [26][48][50] - Cash, cash equivalents, and other financial assets totaled €111.9 million as of December 31, 2025, significantly up from €16.7 million at the end of 2024 [26][49] Strategic Initiatives - Transgene is optimizing its manufacturing processes to prepare for potential pivotal clinical trials [13] - The company is leveraging its proprietary VacDesignR® computational tool to enhance the quality and reliability of its vaccine production [14] - Recent leadership additions aim to accelerate the development of the myvac® platform, with new appointments in key executive roles [19][20]